



MANKIND CONSUMER PRODUCTS PRIVATE LIMITED

CIN: U21002DL2024PTC430710

Registered Office Add: 208, Mankind Pharma Limited, Okhla Industrial Estate, Phase-III, New Delhi-110020

E-mail:- sec.comp@mankindpharma.com

Telephone No.: 1800-1034-400

NOTICE OF EXTRA-ORDINARY GENERAL MEETING

NOTICE is hereby given that the Extra-Ordinary General Meeting of the Members of Mankind Consumer Products Private Limited ("the Company") will be held on Tuesday, August 20, 2024 at 10.00 A.M. at the Registered Office of the Company at 208, Okhla Industrial Estate, Phase-III, New Delhi - 110020, to transact the following business:

SPECIAL BUSINESS:

1. INCREASE IN THE AUTHORIZED SHARE CAPITAL OF THE COMPANY AND ALTERATION OF THE CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION

To Consider and, if thought fit, to pass with or without modification(s), the following resolution as **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 4, 13, 61 and other applicable provisions, if any, of the Companies Act, 2013 (the Act), read with the relevant rules framed thereunder (including any statutory amendment(s), modification(s) or re-enactment(s) thereof for the time being in force) and subject to the authorisation of Articles of Association of the Company, the consent of the Members of the Company be and is hereby accorded to increase the Authorised Share Capital of the Company from existing Rs. 5,00,00,000 (Rupees Five Crores only) divided into 50,00,000 (Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each to Rs. 1,35,00,00,000/- (Rupees One Hundred Thirty Five Crores Only) divided into 50,00,000 (Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each and 13,00,00,000 (Thirteen Crores) Preference Shares of Rs. 10/- (Rupees Ten only) each and consequently the existing Clause V of the Memorandum of Association be and is hereby substituted as follows:

V. The Authorised Share Capital of the Company is Rs. 1,35,00,00,000/- (Rupees One Hundred Thirty Five Crores Only) divided into 50,00,000 (Fifty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten only) each and 13,00,00,000 (Thirteen Crores) Preference Shares of Rs. 10/- (Rupees Ten only) each.

RESOLVED FURTHER THAT Board of Directors of the Company be and is hereby severally authorised to take all such steps as may be necessary, proper and expedient to give effect to this Resolution and also to do all the acts, deeds, matters and things as necessary and incidental thereto."

2. AUTHORISATION TO OFFER, ISSUE AND ALLOT 13,00,00,000 (THIRTEEN CRORES) 0.01% OPTIONALLY CONVERTIBLE NON-CUMULATIVE REDEEMABLE PREFERENCE SHARES OF Rs. 10/- (RUPEES TEN ONLY) EACH

To Consider and, if thought fit, to pass with or without modification(s), the following resolution as **Special Resolution**:

"RESOLVED THAT in accordance with the provisions of Section 55, 62 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 9 of the Companies (Share Capital and Debentures) Rules, 2014 (including any statutory amendment(s), modification(s) or re-enactment(s) thereof for the time being in force) and the Articles of Association of the Company and subject to such other approvals, permissions and sanctions, as may be necessary and subject to such terms, conditions and modifications as may be considered necessary by the Board of Directors, the consent of the members, be and is hereby accorded to offer, issue and allot up to 13,00,00,000 (Thirteen Crores) 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares ("Preference Shares" or "OCPS") of Rs. 10/- (Rupees Ten only) each, at par, aggregating to Rs. 1,30,00,00,000 (Rupees One Hundred Thirty Crores only) to Mankind Pharma Limited (Holding Company), on Right Basis, in one or more tranche(s), on the terms and conditions given below, namely-

1. The OCPS will be issued at Face Value of Rs. 10/- (Rupees Ten only) per share.
2. Dividend Rate will be 0.01% (zero-point zero one percent) per annum which will remain fixed over the tenure of OCPS.
3. The tenure of OCPS shall be upto July 31, 2044.
4. The OCPS will carry non-cumulative dividend right.
5. The OCPS may be converted or redeemed either fully or partially, in one or more tranches, at the option of issuer Company at any time during the tenure of OCPS as per below:

If OCPS is converted: 1 OCPS of Rs. 10/- (Rupees Ten only) each shall be converted into 1 Equity Share of Rs. 10/- (Rupees Ten only) each.

If OCPS is redeemed in cash: The redemption will be made out of the following two values, whichever is higher:

At fair value of shares of Mankind Consumer Products Private Limited (MCPPL) on the date of redemption.

OR

Issue Price of OCPS i.e. Rs. 10/- (Rupees Ten only) for each OCPS.

6. The OCPS will carry Preferential Right vis-à-vis Equity shares of the Company with respect to the payment of dividend and repayment of capital during winding up.
7. The OCPS shall be non-participating in the surplus funds, surplus assets and profits, on winding up which may remain after the entire capital has been repaid.
8. The OCPS shall carry voting rights as may be prescribed under the provisions of Section 47(2) and other applicable provisions of the Companies Act, 2013 (including any statutory modifications or re-enactments thereof for the time being in force).
9. The terms of the OCPS can be modified upon receipt of the consent from the OCPS holder.

RESOLVED FURTHER THAT for the purpose of giving effect to the aforesaid resolution, the Board of Directors of the Company be and is hereby authorised to do all such acts, deeds, matters and things as it may, in its absolute discretion, deems necessary, proper or desirable for such purpose, including but not limited to execution of various deeds, documents, writings, agreements, and also to modify, accept and give effect to the modifications therein and the terms and conditions of the issue, as may be considered necessary and to settle all queries or doubts that may arise in the proposed issue, without being required to seek any further consent or approval of the Members.

RESOLVED FURTHER THAT subject to applicable laws, the Board be and is hereby also authorized to delegate, all or any of the powers herein conferred, to any Director(s) or Officer(s) of the Company and to revoke and substitute such delegation from time to time, as deemed fit by the Board, to give effect to the aforesaid resolution."

3. APPOINTMENT OF MR. AKHLAS AHMED AS THE WHOLE-TIME DIRECTOR OF THE COMPANY

To Consider and, if thought fit, to pass with or without modification(s), the following resolution as **Ordinary Resolution**:

"RESOLVED THAT pursuant to the Sections 196, 203 read with Schedule V and other applicable provisions,

if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any amendment, modification or re-enactment thereof for the time being in force) the consent of the members be and is hereby accorded to appoint Mr. Akhlas Ahmed (DIN: 08973480) as a Whole Time Director of the Company with effect from August 8, 2024 for a period of 5 years on no remuneration basis.

RESOLVED FURTHER THAT Mr. Akhlas Ahmed, Whole Time Director, be and is hereby authorized to ensure compliance with the duties, obligations and requirements of various statutes/laws and to maintain and keep required records as may be required under any of the aforesaid statutes/laws in the general course of business of the Company.

RESOLVED FURTHER THAT Board of Directors of the Company be and is hereby severally authorised to take all such steps as may be necessary, proper and expedient to give effect to this Resolution and also to do all the acts, deeds, matters and things as necessary and incidental thereto."

4. APPOINTMENT OF MR. SATISH KUMAR SHARMA AS THE DIRECTOR OF THE COMPANY

To Consider and, if thought fit, to pass with or without modification(s), the following resolution as **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 152, 161 and other applicable provisions, if any, of the Companies Act, 2013, read with Companies (Appointment and Qualification of Directors) Amendment Rules, 2023 and other applicable provisions and Rule, if any, of the Companies Act, 2013 ("the Act") (including any statutory amendment(s), modification(s) or re-enactment(s) thereof for the time being in force) the consent of members be and is hereby accorded to appoint Mr. Satish Kumar Sharma (DIN: 07615602), who was appointed as an Additional Director of the Company with effect from 11th July, 2024 under Section 161 of the Companies Act, 2013, as the Director of the Company.

RESOLVED FURTHER THAT Board of Directors of the Company be and is hereby severally authorised to take all such steps as may be necessary, proper and expedient to give effect to this Resolution and also to do all the acts, deeds, matters and things as necessary and incidental thereto."

**By the order of Board of Directors of
Mankind Consumer Products Private Limited**

Kuldeep Tiwari
Company Secretary
Membership No.: F12889

Date: July 25, 2024

Place: New Delhi

Notes:

1. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, relating to special business to be transacted at the meeting is annexed.
2. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND, TO VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY.** Proxies in order to be effective, should be duly completed, stamped and signed and must be deposited at the Registered Office of the Company not less than forty-eight hours before the commencement of the Meeting. A person can act as a proxy on behalf of Members not exceeding 50 and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A Member holding more than ten percent of total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
3. During the period beginning 24 hours before the time fixed for the commencement of Meeting and ending with the conclusion of the Meeting, a Member would be entitled to inspect the proxies lodged at any time during the business hours of the Company.
4. A Corporate Member intending to send its authorised representatives to attend the Meeting in terms of Section 113 of the Companies Act, 2013 is requested to send to the Company a certified copy of the Board Resolution authorizing such a representative to attend and vote on its behalf at the Meeting.
5. Members are requested to bring the attendance slips duly filled in for attending the Meeting. Members holding shares in dematerialised form are requested to write their client ID and DP ID numbers.
6. All relevant documents referred to in the accompanying Notice and Explanatory Statement shall be available for inspection by the Members of the Company during normal business hours at the registered office of the Company and also at the place of the meeting on the meeting day.
7. Route-map to the venue of the Meeting is provided at the end of the Notice.

Intentionally left blank

EXPLANATORY STATEMENT U/S 102 OF THE COMPANIES ACT, 2013

ITEM NO. 1:

The Members may note that the Company was incorporated with a purpose to carry out the Over the Counter ("OTC") Business, which was transferred to it from the Mankind Pharma Limited i.e., Holding Company on a slump sale basis. In order to pursue the purpose of the said slump sale and to carry out the OTC Business, the Company will require more funds in future.

It is therefore proposed to increase the Authorized Share Capital of the Company from present ₹5,00,00,000 (Rupees Five Crores only) divided into 50,00,000 (Fifty Lakhs) Equity Shares of ₹10/- (Rupees Ten only) each to ₹1,35,00,00,000/- (Rupees One Hundred Thirty Five Crores) divided into 50,00,000 (Fifty Lakhs) Equity Shares of ₹10/- (Rupees Ten only) each and 13,00,00,000 (Thirteen Crores) Preference Shares of ₹10/- (Rupees Ten only) each aggregating to ₹1,30,00,00,000 (Rupees One Hundred Thirty Crores only).

The proposed increase in the Authorised Share Capital requires the approval of Members in General Meeting by way of an Ordinary Resolution. Consequent upon increase in the Authorised Share Capital, the Memorandum of Association of the Company will require alteration to reflect the increased Authorized Share Capital.

Accordingly, the Board recommend passing of an Ordinary Resolution as set out at Item No. 1 of the accompanying Notice.

None of the Directors of the Company including their relatives is in any way, concerned or deemed to be interested in the proposed resolution.

A copy of the Memorandum of Association of the Company together with the proposed alteration is available for inspection at Registered Office of the Company until the start of the Extra-ordinary General Meeting.

ITEM NO. 2:

The Board of Directors at their meeting held on Thursday, August 8, 2024 has recommended, the offer and issue of 13,00,00,000 (Thirteen Crores) 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares ("Preference Shares" or "OCPS") of ₹10/- (Rupees Ten only) each, at par, aggregating to ₹1,30,00,00,000 (Rupees One Hundred Thirty Crores only) to Mankind Pharma Limited (Holding Company), on Right Basis, in one or more tranche(s) subject to increase in Authorized Share Capital of the Company.

The OCPS shall carry dividend @ 0.01% which shall be non-cumulative. The OCPS may be converted/ redeemed either fully or partially at any-time, in one or more tranches, during the tenure of OCPS at the option of the issuer Company subject to the compliance with the provisions of the Act.

Section 55 of the Companies Act, 2013 read with Rule 9 of the Companies (Share Capital and Debentures) Rules, 2014, requires a company to obtain approval of the members, by way of a Special Resolution for issuance of Preference Shares. Thus, the approval of the Members is being sought, by way of a Special Resolution, to offer and issue Preference Shares, in one or more tranche(s) on a right basis.

A statement of complete material facts concerned with and relevant to the offer and issue of the Preference Shares as required under Rule 9 (3) of the Rules is as under:

1.	Issue size, number of Preference Shares to be issued and nominal value of each share	Issue Size: ₹1,30,00,00,000 (Rupees One Hundred Thirty Crores only) No. of Preference Shares: 13,00,00,000 (Thirteen Crores) Nominal Value: ₹10/- (Rupees Ten only) each.
2.	The nature of such shares	Redeemable, Non-Cumulative, Non-Participating and Optionally Convertible Preference Shares.
3.	The objectives of the issue	The objects of the issue are: a) to enhance the capital base of the Company; and b) to pursue the business objective of the Company.
4.	The manner of issue of shares	The Preference Shares are issued on a Right Basis in accordance with the provisions of Section 62 (1) (a) of the Act to existing equity shareholders.
5.	The price at which such shares are proposed to be issued;	at Par
6.	The basis on which the price has been arrived at	Preference Shares are being issued at par.
7.	The terms of issue and rate of dividend on each share	As per the Special Resolution proposed above.
8.	The terms, tenure, mode and manner of redemption	The redemption will be made out of the following two values, whichever is higher: • At Fair Value of shares of Mankind Consumer Products Private Limited on the date of redemption. OR • Issue Price of OCPS i.e., ₹10/- (Rupees Ten only) for each OCPS.

9.	The terms of conversion	1 OCPS of ₹10/- (Rupees Ten only) each shall be converted into 1 Equity Share of ₹10/- (Rupees Ten only) each.												
10.	The current shareholding pattern of the Company:	<p style="text-align: center;">EQUITY SHAREHOLDERS</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center;">S. No</th> <th style="text-align: center;">Name of Shareholder</th> <th style="text-align: center;">% of Holding</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">1.</td> <td>Mankind Pharma Limited</td> <td style="text-align: center;">100.00%</td> </tr> <tr> <td style="text-align: center;">2.</td> <td>Mr. Ramesh Juneja (On behalf of Mankind Pharma Limited)</td> <td style="text-align: center;">0.00%</td> </tr> <tr> <td colspan="2" style="text-align: right;">TOTAL</td><td style="text-align: center;">100.00%</td></tr> </tbody> </table>	S. No	Name of Shareholder	% of Holding	1.	Mankind Pharma Limited	100.00%	2.	Mr. Ramesh Juneja (On behalf of Mankind Pharma Limited)	0.00%	TOTAL		100.00%
S. No	Name of Shareholder	% of Holding												
1.	Mankind Pharma Limited	100.00%												
2.	Mr. Ramesh Juneja (On behalf of Mankind Pharma Limited)	0.00%												
TOTAL		100.00%												
11.	The expected dilution in Equity Share Capital upon conversion of Preference Shares	Nil, since OCPS, if issued will be to the Existing Equity Shareholders.												

The issue of OCPS is in accordance with the provisions of the Articles of Association of the Company. The documents referred in Item No. 2 above, in respect of which Explanatory Statement has been provided, are available for inspection by the Members of the Company during normal business hours at the Registered Office of the Company and also at the place of the meeting on the meeting day.

The Board of Directors of the Company accordingly recommend the resolution as set out in Item No. 2 for your approval as Special Resolution.

None of the Directors of the Company including their respective relatives is in any way, concerned or deemed to be interested in the proposed resolution.

ITEM NO. 3:

Pursuant to the Sections 196, 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 ("Act") the Board of Directors ("Board"), of the Company had appointed Mr. Akhlas Ahmed (DIN: 08973480) as Whole-time Director of the Company for a period of 5 years with effect from August 8, 2024 on no remuneration basis, subject to the approval of members and are eligible to be appointed as a Whole-time Director of the Company.

Having regard to the qualifications, experience and knowledge, the Board considers that his association would be of immense benefit to the Company. A brief profile of the Directors is provided as an annexure to this Notice.

Accordingly, the consent of the members is sought by way of Ordinary Resolution as set out in Item No. 3 above.

None of the Directors (except Mr. Akhlas Ahmed) of the Company including their respective relatives is in any way, concerned or deemed to be interested in the proposed resolution.

The Board recommends the resolution as set out in Item No. 3 for approval of the members.

S. No.	Particulars of the Information	Details
1.	Name	Mr. Akhlas Ahmed
2.	Age	45 Years
3.	Qualifications	B. Pharma
4.	Experience	He has experience of more than 20 years in Pharma Industry.
5.	Terms & conditions of appointment	As mentioned in the resolution above at Item No. 3 of the notice convening this Meeting read with Explanatory Statement thereto.
6.	Remuneration sought to be paid	NIL
7.	Remuneration last drawn	NIL
8.	Date of First Appointment on the Board	August 8, 2024
9.	Shareholding in the Company as on March 31, 2024	NIL
10.	Relationship with other Directors, Manager and other Key Managerial Personnel of the Company	Not related to any Directors, Manager and Key Managerial Personnel of the Company
11.	Number of Meetings of Board attended during the year and other Directorships, Membership/ Chairmanship of Committees of other Boards	<p>Number of Meetings of Board attended during the year - Nil</p> <p>He holds the position of Director / Designated Partner in the following Body Corporates:</p> <ol style="list-style-type: none"> 1. Mankind Prime Labs Private Limited 2. Mankind Life Sciences Private Limited 3. Mankind Agritech Private Limited 4. Mankind Medicare Private Limited 5. Packtime Innovations Private Limited 6. Sirmour Remedies Private Limited 7. Copmed Pharmaceuticals Private Limited 8. Relax Pharmaceuticals Private Limited 9. Mediforce Healthcare Private Limited 10. Mankind Petcare Private Limited (Formerly Known as Mankind Consumer Healthcare Private Limited)

	<p>Chairmanship of Committees:</p> <ol style="list-style-type: none"> 1. Audit Committee - Copmed Pharmaceuticals Private Limited 2. Nomination and Remuneration Committee - Copmed Pharmaceuticals Private Limited 3. Corporate Social Responsibility Committee - Copmed Pharmaceuticals Private Limited 4. Audit Committee - Relax Pharmaceuticals Private Limited 5. Nomination and Remuneration Committee - Relax Pharmaceuticals Private Limited 6. Corporate Social Responsibility Committee - Relax Pharmaceuticals Private Limited 7. Corporate Social Responsibility Committee – Mediforce Healthcare Private Limited 8. Nomination and Remuneration Committee – Packtime Innovations Private Limited <p>Membership of Committees –</p> <ol style="list-style-type: none"> 1. Audit Committee – Packtime Innovations Private Limited
--	--

ITEM NO. 4:

The Board of Directors ("Board"), had appointed Mr. Satish Kumar Sharma (DIN: 07615602) as Additional Director of the Company with effect from July 11, 2024. Pursuant to the provisions of Section 161 of the Companies Act, 2013 ("Act"), he holds the office up to the date of the ensuing Annual General Meeting ("AGM") and are eligible to be appointed as a Director of the Company. The Board of Directors have already recommended his appointment as Director of the Company, to the Members for their approval.

Having regard to the qualifications, experience and knowledge, the Board considers that his association would be of immense benefit to the Company. A brief profile of the Directors is provided as an annexure to this Notice.

Accordingly, the consent of the members is sought by way of Ordinary Resolution as set out in Item No. 4 above.

None of the Directors (except Mr. Satish Kumar Sharma) of the Company including their respective relatives is in any way, concerned or deemed to be interested in the proposed resolution.

The Board recommends the resolution as set out in Item No. 4 for approval of the members.

S. No.	Particulars of the Information	Details
1.	Name	Mr. Satish Kumar Sharma
2.	Age	51 Years
3.	Qualifications	B. Pharma and MBA
4.	Experience	Mr. Satish Kumar Sharma holds a bachelor's degree in pharmacy from Gulbarga University, Karnataka. He is Whole Time Director of Mankind Pharma Limited and was previously associated with T.C. Health Care Private Limited as senior officer – validation, Nicholas Piramal India Limited as Assistant Manager – production and Wockhardt Limited as a supervisor
5.	Terms & conditions of appointment	As mentioned in the resolution above at Item No. 4 of the notice convening this Meeting read with Explanatory Statement thereto.
6.	Remuneration sought to be paid	NIL
7.	Remuneration last drawn	NIL
8.	Date of First Appointment on the Board	July 11, 2024
9.	Shareholding in the Company as on March 31, 2024	NIL
10.	Relationship with other Directors, Manager and other Key Managerial Personnel of the Company	Not related to any Directors, Manager and Key Managerial Personnel of the Company
11.	Number of Meetings of Board attended during the year and other Directorships, Membership/ Chairmanship of Committees of other Boards	<p>Number of Meetings of Board attended during the year - 3</p> <p>He holds the position of Director / Designated Partner in the following Body Corporates:</p> <ol style="list-style-type: none"> 1. Mankind Pharma Limited 2. Mankind Medicare Private Limited 3. Appian Properties Private Limited 4. Pharmaforce Medex Private Limited (Formerly Known as Pharmaforce Excipients Private Limited) 5. Penta Latex LLP (as Nominee Partner to the Body Corporate) <p>Chairmanship of Committees – Nil</p> <p>Membership of Committees – Nil</p>

FORM NO. MGT -11

Proxy Form

[Pursuant to the provisions of Section 105 (6) of the Companies Act, 2013 and Rule 19 (3) of the Companies (Management and Administration) Rules, 2014]

CIN: U21002DL2024PTC430710

Name of the Company: Mankind Consumer Products Private Limited

Registered Office: 208, Okhla Industrial Estate, Phase – III, New Delhi - 110020

Name of the Member(s):

Registered Address:

E-mail ID

Folio No. / Client ID:

DP ID:

I/We being the Member(s) of _____ Equity Shares of Rs. 10/- each of the above-named Company, hereby appoint:

1. Name: _____

Address: _____

E-mail Id: _____

Signature: _____, or failing him

2. Name: _____

Address: _____

E-mail Id: _____

Signature: _____

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Annual General Meeting of the Company, to be held on Tuesday, August 20, 2024 at 10:00 A.M. at its Registered Office at 208, Okhla Industrial Estate, Phase – III, New Delhi- 110020 and at any adjournment(s) thereof, in respect of the resolutions, as indicated below:

Resolution No:

1. Increase in the Authorized Share Capital of the Company and alteration of the capital clause of the Memorandum of Association
2. Authorisation to offer, issue and allot 13,00,00,000 (thirteen crores) 0.01% optionally convertible non-cumulative redeemable preference shares of Rs. 10/- (rupees ten only) each
3. Appointment of Mr. Akhlas Ahmed as the whole-time director of the Company
4. Appointment of Mr. Satish Kumar Sharma as the director of the Company

Signed this day of2025.

Signature of Shareholder: _____

Affix Revenue
Stamp

Signature of the Proxy holder(s): _____

Note: This Form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.

ATTENDANCE SLIP

Extra-Ordinary General Meeting – August 20, 2024

Name of the Member in Block Letters:

Folio/DP ID-Client ID:

No. of shares held:


I/We hereby record my/our presence at the Extra-Ordinary General Meeting of the Members of the Company to be held on Tuesday, August 20, 2024 at 10:00 A.M. at 208, Okhla Industrial Estate, Phase-III, New Delhi - 110020.

Signature of the Member's

Note: Please fill this attendance slip and hand it over at the entrance of the hall.

Intentionally left blank

**ROUTE MAP OF THE VENUE OF THE EXTRA-ORDINARY GENERAL MEETING
OF
MANKIND CONSUMER PRODUCTS PRIVATE LIMITED**



Mankind Consumer Products Private Limited

Registered Office:

208, Okhla Industrial Estate, Phase-III,
New Delhi - 110020

CIN: U21002DL2024PTC430710

Venue of EGM:

208, Okhla Industrial Estate, Phase-III,
New Delhi - 110020